Issue 49, 2022

ZIF-8 with cationic defects toward efficient 125I2 uptake for in vitro radiotherapy of colon cancer

Abstract

Introducing 2,3-dimethyl-1H-imidazol-3-ium iodide (Dmim) as a monodentate ligand during the preparation of ZIF-8 yields ZIF-8 + (50) and ZIF-8 + (38) with cationic ‘missing linker’ defects. ZIF-8 + (38) adsorbs 125I2 and the resulting radioactive host–guest complex exhibits in vitro cytotoxicity comparable to that of Na125I against colon cancer cell line CT26.

Graphical abstract: ZIF-8 with cationic defects toward efficient 125I2 uptake for in vitro radiotherapy of colon cancer

Supplementary files

Article information

Article type
Communication
Submitted
31 Dec 2021
Accepted
23 May 2022
First published
23 May 2022

Chem. Commun., 2022,58, 6942-6945

ZIF-8 with cationic defects toward efficient 125I2 uptake for in vitro radiotherapy of colon cancer

X. Tian, Y. Liu, Y. Li, X. Qiu, W. Zhang, D. J. Young and Q. Chen, Chem. Commun., 2022, 58, 6942 DOI: 10.1039/D1CC07304D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements